ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Update

ProQR Therapeutics N.V. (NASDAQ:PRQR) saw a significant drop in short interest in April. As of April 15th, there was short interest totaling 1,261,281 shares, a drop of 24.4% from the March 31st total of 1,667,465 shares. Based on an average daily volume of 736,794 shares, the days-to-cover ratio is presently 1.7 days. Currently, 1.3% of the company’s stock are sold short.

ProQR Therapeutics Price Performance

NASDAQ PRQR traded up $0.03 during trading on Thursday, hitting $1.57. The company’s stock had a trading volume of 488,389 shares, compared to its average volume of 525,980. The company has a market cap of $165.42 million, a PE ratio of -3.41 and a beta of 0.10. The business’s 50 day simple moving average is $1.68 and its 200-day simple moving average is $1.94. ProQR Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $5.53 million during the quarter, compared to analyst estimates of $6.12 million. ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%. Analysts expect that ProQR Therapeutics will post -0.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PRQR shares. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research report on Friday, March 13th. Wall Street Zen raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Tuesday, April 21st. Oppenheimer started coverage on ProQR Therapeutics in a research report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective on the stock. Finally, Chardan Capital reissued a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Thursday, April 9th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Institutional Investors Weigh In On ProQR Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. lifted its holdings in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the period. Guggenheim Capital LLC acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth about $35,000. Moody Lynn & Lieberson LLC acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth about $50,000. Invesco Ltd. acquired a new stake in shares of ProQR Therapeutics during the fourth quarter worth about $51,000. Finally, Fifth Third Bancorp acquired a new stake in shares of ProQR Therapeutics during the third quarter worth about $64,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.